Algert Global LLC Tricida, Inc. Transaction History

Algert Global LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$8.51 - $13.6 $18,985 - $30,341	2,231 Added 20.04%	13,361 $140,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $81,360 - $131,890	11,130 New	11,130 $108,000
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $74,676 - $108,000	-10,160 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $42,570 - $97,129	10,160 New	10,160 $97,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.